SVB Leerink Maintains Market Perform on Abeona Therapeutics, Raises Price Target to $6
SVB Leerink analyst Mani Foroohar maintains Abeona Therapeutics (NASDAQ:ABEO) with a Market Perform and raises the price target from $5 to $6.
Cantor Bullish On Abeona Saying Recent Trial Data ‘Best Case Scenario’
Cantor Fitzgerald raised the price target on Abeona Therapeutics Inc (NASDAQ:ABEO) from $22 to $40 after adjusting the market model/ increasing the…
Abeona Therapeutics Announces Phase 3 VIITAL Study Met Two Co-Primary Efficacy Endpoints
Co-primary endpoint measuring >50% wound healing, other endpoints measuring >75% and complete wound healing at six months all met
Co-primary endpoint measuring pain reduction at six
Why Laser Photonics Shares Surged By Around 19%; Here Are 70 Biggest Movers From Friday
Gainers
Agrify Corporation (NASDAQ: AGFY) climbed 53.8% to close at $1.45.
FedNat Holding Company (NASDAQ: FNHC) gained 48% to settle at $0.52.
Why NVIDIA, Microsoft And Amazon Shares Traded Lower; Here Are 73 Biggest Movers From Friday
Gainers
Innovative Eyewear, Inc. (NASDAQ: LUCY) climbed 61.4% to close at $2.63 on abnormally-high volume. The company released its October investor presentation yesterday.
How Is The Market Feeling About Abeona Therapeutics?
Abeona Therapeutics's (NASDAQ:ABEO) short percent of float has fallen 9.04% since its last report. The company recently reported that it has 177 thousand shares sold short, which is 3.02% of all regular shares that are available for trading.
12 Health Care Stocks Moving In Friday’s Intraday Session
Gainers
Inventiva (NASDAQ:IVA) shares increased by 44.0% to $5.88 during Friday's regular session. The market value of their outstanding shares is at $247.6 million.
Why Aehr Test Systems Shares Are Trading Higher By Over 19%, Here Are 51 Stocks Moving In Friday’s Mid-Day Session
Gainers
Innovative Eyewear, Inc. (NASDAQ: LUCY) jumped 108% to $3.3943 on abnormally-high volume. The company released its October investor presentation yesterday.
Abeona Therapeutics Announces Completion Of Patient Follow-Up In Pivotal Phase 3 VIITAL Study Ff EB-101
Abeona Therapeutics Inc. (NASDAQ:ABEO) today announced that the last patient has completed their 6-month follow-up visit in Abeona’s pivotal Phase 3 VIITAL™ study of its investigational autologous, engineered
Abeona Therapeutics Q2 EPS $(2.08) Up From $(4.00) YoY
Abeona Therapeutics (NASDAQ:ABEO) reported quarterly losses of $(2.08) per share. This is a 48 percent increase over losses of $(4.00) per share from the same period last year.